Literature DB >> 10493397

Pathophysiology of L-dopa-induced dyskinesias.

P J Bédard1, P J Blanchet, D Lévesque, J J Soghomonian, R Grondin, M Morissette, M Goulet, F Calon, P Falardeau, B Gomez-Mancilla, J P Doucet, G S Robertson, T DiPaolo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10493397

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  14 in total

1.  Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4.

Authors:  Richard Williams; Ya Zhou; Colleen M Niswender; Qingwei Luo; P Jeffrey Conn; Craig W Lindsley; Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2010-06-16       Impact factor: 4.418

2.  Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.

Authors:  Souha Mahmoudi; Pershia Samadi; François Gilbert; Bazoumana Ouattara; Marc Morissette; Laurent Grégoire; Claude Rouillard; Thérèse Di Paolo; Daniel Lévesque
Journal:  Neurobiol Dis       Date:  2009-07-25       Impact factor: 5.996

3.  Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

Authors:  Joseph D Panarese; Darren W Engers; Yong-Jin Wu; Joanne J Bronson; John E Macor; Aspen Chun; Alice L Rodriguez; Andrew S Felts; Julie L Engers; Matthew T Loch; Kyle A Emmitte; Arlindo L Castelhano; Michael J Kates; Michael A Nader; Carrie K Jones; Anna L Blobaum; P Jeffrey Conn; Colleen M Niswender; Corey R Hopkins; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2018-10-16       Impact factor: 4.345

4.  Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.

Authors:  Pauline Belujon; Daniel J Lodge; Anthony A Grace
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

Review 5.  Parkinson's disease: medical treatment of moderate to advanced disease.

Authors:  Oksana Suchowersky
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

6.  Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.

Authors:  Danqing Xiao; Jared J Cassin; Brian Healy; Thomas C Burdett; Jiang-Fan Chen; Bertil B Fredholm; Michael A Schwarzschild
Journal:  Brain Res       Date:  2010-09-07       Impact factor: 3.252

Review 7.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

9.  Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.

Authors:  Justin D Oh; Alfred I Geller; Guo rong Zhang; Thomas N Chase
Journal:  Brain Res       Date:  2003-05-02       Impact factor: 3.252

10.  Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.

Authors:  Han Soo Yoo; Seok Jong Chung; Su Jin Chung; Hyojeong Moon; Jung Su Oh; Jae Seung Kim; Jin Yong Hong; Byoung Seok Ye; Young Ho Sohn; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-26       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.